DUBLIN – U.K. start-up Critical Pressure Ltd. raised £10 million (US$13.2 million) in a series A round to move a selective inhibitor of dimethylarginine dimethylaminohydrolase 1 (DDAH1) into clinical development in intensive care patients with severe sepsis.